EUCTR2004-003896-35-IT进行中（未招募）不适用
Phase I/II study on concomitant and adjuvant Temozolomide and Radiotherapy with or without PTK787/ZK222584 in newly diagnosed GBM
E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER0 个研究点目标入组 220 人开始时间: 2007年2月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Phase I/II study on concomitant and adjuvant Temozolomide and Radiotherapy with or without PTK787/ZK222584 in newly diagnosed GBMGlioblastoma multiformeEUCTR2004-003896-35-DEEuropean Organisation for Research and Treatment of Cancer220
进行中（未招募）
不适用
Phase I/II study on concomitant and adjuvant Temozolomide and Radiotherapy with or without PTK787/ZK222584 in newly diagnosed GBMGlioblastoma multiformeEUCTR2004-003896-35-GBEuropean Organisation for Research and Treatment of Cancer220
进行中（未招募）
1 期
Phase I/II study on concomitant and adjuvant Temozolomide and Radiotherapy with or without PTK787/ZK222584 in newly diagnosed GBMMedDRA version: 7.1Level: PTClassification code 10018337Glioblastoma multiformeEUCTR2004-003896-35-ATEuropean Organisation for Research and Treatment of Cancer220
进行中（未招募）
不适用
Phase I/II study on concomitant and adjuvant Temozolomide and Radiotherapy with or without PTK787/ZK222584 in newly diagnosed GBMGlioblastoma multiformeEUCTR2004-003896-35-BEEuropean Organisation for Research and Treatment of Cancer220
已完成
3 期
A randomised phase III Trial on concurrent and adjuvant Temozolomide chemotherapy in non 1p/19q deleted anaplastic glioma to evaluate overall survival.Anaplastic GliomaNeurological - Other neurological disordersCancer - Other cancer typesACTRN12609000485235niversity of Sydney751